| Autor: |
Stober CB; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom. c.stober@doctors.org.uk, Jeronimo SM, Pontes NN, Miller EN, Blackwell JM |
| Jazyk: |
angličtina |
| Zdroj: |
The American journal of tropical medicine and hygiene [Am J Trop Med Hyg] 2012 Oct; Vol. 87 (4), pp. 663-70. Date of Electronic Publication: 2012 Jul 23. |
| DOI: |
10.4269/ajtmh.2012.12-0180 |
| Abstrakt: |
Visceral leishmaniasis (VL) is fatal if untreated, and there are no vaccines for this disease. High levels of CD4-derived interferon-γ (IFN-γ) in the presence of low levels of interleukin-10 (IL-10) predicts vaccine success. Tumor necrosis factor-α (TNF-α) is also important in this process. We characterized human immune responses in three groups exposed to Leishmania infantum chagasi in Brazil: 1) drug-cured VL patients (recovered VL); 2) asymptomatic persons with positive Leishmania-specific delayed-type hypersensitivity skin reactions (DTH+); and 3) DTH-negative household contacts. Magnitude of DTH correlated with crude Leishmania antigen-driven IFN-γ, TNF-α, and IL-5, but not IL-10. DTH+ persons showed equivalent levels of IFN-γ, but higher levels of IL-10, to tryparedoxin peroxidase and Leishmania homolog of receptor for activated C kinase compared with recovered VL patients. The IFN-γ:IL-10 and TNF-α:IL-10 ratios were higher in recovered VL patients than in DTH+ persons. Seven of 11 novel candidates (R71, L37, N52, L302.06, M18, J41, and M22) elicited cytokine responses (36-71% of responders) in recovered VL patients and DTH+ persons. This result confirmed their putative status as cross-species vaccine/immunotherapeutic candidates. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
